Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Debt / NOTE 1.000% 8/1
-
Market price (% of par)
-
93.7%
-
Total 13F principal
-
$15,752,492,283
-
Principal change
-
+$15,668,061,283
-
Total reported market value
-
$631,952,021
-
Number of holders
-
63
-
Value change
-
+$552,410,785
-
Number of buys
-
60
Institutional Holders of HALOZYME THERAPEUTICS INC - NOTE 1.000% 8/1 as of Q3 2023
As of 30 Sep 2023,
HALOZYME THERAPEUTICS INC - NOTE 1.000% 8/1 was held by
63 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$15,752,492,283
in principal (par value) of the bond.
The largest 10 bondholders included
M&G INVESTMENT MANAGEMENT LTD, MACKAY SHIELDS LLC, Linden Advisors LP, ADVENT CAPITAL MANAGEMENT /DE/, Calamos Advisors LLC, WOLVERINE ASSET MANAGEMENT LLC, CITADEL ADVISORS LLC, STATE STREET CORP, Polar Asset Management Partners Inc., and Voya Investment Management LLC.
This page lists
65
institutional bondholders reporting positions
for the Q3 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.